A case of dupilumab‐induced psoriasis‐like eruption treated with baricitinib
Abstract Dupilumab is a humanized monoclonal antibody against the interleukin (IL)‐4 receptor alpha chain that inhibits IL‐4 and IL‐13 signalling. It is one of the systemic treatments for patients with moderate‐to‐severe atopic dermatitis (AD), which provides favourable safety and efficacy. We repor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.338 |